Supplementary Table 2 Comparison of CD19high patients and CD19low patients of the retrospective study group cohort and the prospective study group cohort.
CD19low group | CD19high group | Level of significance | |
|---|---|---|---|
Retrospective study group | n = 58 | n = 36 | |
Age (years) | 63.8 (56–72) | 62.7 (56–72) | 0.613 |
Disease duration (years) | 11.4 (7.1–22.6) | 19 (5.8–27.7) | 0.446 |
ESR (mm/h) | 35.9 (22.83–3.19) | 31.52 (21.72–3.9) | 0.393 |
C-reactive protein (mg/l) | 27.6-(6.5–60) | 15.7 (7.18–40.28 | 0.204 |
Serum IgM (g/l) | 1.65 (1.20–2.26) | 1.92 (1.60–2.61) | 0.022 |
Serum IgG (g/l) | 10.45 (9.09–11.70) | 10.50 (9.54–13.00) | 0.498 |
Serum IgA (g/l) | 2.67 (1.89–3.73) | 2.67 (1.88–3.91) | 0.724 |
RF IgM (IU/ml) | 134.8 (84–257) | 187 (110–207) | 0.182 |
RF IgA 9 IU/ml) | 75 (33.5–128.75) | 31.5 (13.5–106.5) | 0.02 |
ANF (titer) | 1:160 (0–1:320) | 1:160 (0–1:1120) | 0.861 |
Circulating immune complexes(g/l) | 4.6 (3.32–9.15) | 4.45 (3–5.8) | 0.607 |
Prospective study group | n = 36 | n = 34 | |
C-reactive protein (mg/l) | 14 (5–25.5) | 5.4 (0–9.2) | 0.013 |
Serum IgM (g/l) | 1.07 (0.79–1.4) | 1.19 (0.88–1.43) | 0.618 |
Serum IgG (g/l) | 11.5 (10.22–13.7) | 12.7 (11–14.2) | 0.371 |
Serum IgA (g/l) | 3.08 (2.04–3.86) | 2.35 (1.78–3.02) | 0.062 |
RF IgM (IU/ml) | 132 (31.1–253) | 65.5 (0–136) | 0.099 |
RF IgA (IU/ml) | 63.5 (12–155.8) | 0 (0–8) | < 0.001 |